BRAF and melanoma: Nonsteroidal anti-inflammatory drugs (NSAID), diclofenac and lumiracoxib, increased the anti-glycolytic impact of BRAF inhibitors and prevented RAF-inhibitor induced metabolic reprogramming towards OXPHOS, thus, leading to an enhanced sensitivity of melanoma cells to BRAF inhibitors and delayed onset of treatment resistance [206].